Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says
Despite an initial dip in sales during Q1 stemming from a class action suit, Sanofi-Aventis says growth of the insomnia drug returned to previous levels.
Despite an initial dip in sales during Q1 stemming from a class action suit, Sanofi-Aventis says growth of the insomnia drug returned to previous levels.